Rheumatology Advisor—May 18, 2018
Rheumatology Advisor interviewed HSS rheumatologist Robert F. Spiera, MD, about risk factors and treatment strategies for pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc).
"PAH is an important complication of SSc, and one of the leading causes of mortality in this disease. Although it occurs in a minority of patients, clinicians must be attentive to it, as it can emerge at any point over the course of the disease," Dr. Spiera explained.
In terms of screening, Dr. Spiera noted that "a good history and physical are important at each visit".
"Treatment of SSc-associated PAH uses the same strategies as those used for idiopathic PAH, including vasodilators, endothelin receptor antagonists, prostacyclins, and in many patients, combination therapy," added Dr. Spiera.
Read the full article at rheumatologyadvisor.com